Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "daiichi sankyo company"

Daiichi Sankyo Establishes New U.S. HQ
Contract Pharma

Daiichi Sankyo to open new U.S. headquarters in New Jersey

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd. , will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize ... Center Watch, 4 days ago
[x]  

Daiichi Sankyo doses first subject in Duchenne muscular dystrophy study

(MarketLine via COMTEX News Network) -- Daiichi Sankyo Company, Limited has dosed the first subject in the first clinical trial with DS-5141b, which is jointly developing with the Orphan Disease Treatment Institute Co., Ltd., or ODTI, for the ...
 PredictWallStreet1 day ago Medical University, Daiichi Sankyo & Mitsubishi UFJ Capital to open innovation research to develop new capillary stem cells  PharmaBiz3 weeks ago DAIICHI SANKYO : Commencement of First-in-Human Clinical Trial for New Molecular Targeting Drug, Co-Developed with The University of Tokyo and National Cancer Center, to Treat Malignant Lymphoma (Including Adult T-cell Leukemia-Lymphoma)  4 Traders3 weeks ago DAIICHI SANKYO : Open innovation research on new stem cells by Asahikawa Medical University, Daiichi Sankyo, and Mitsubishi UFJ Capital  4 Traders3 weeks ago

BRIEF-Portola signs agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban

April 4 Portola Pharmaceuticals Inc * Portola pharmaceuticals enters into clinical collaboration agreement with daiichi sankyo to develop andexanet alfa with edoxaban in japan * Clinical collaboration agreement with daiichi sankyo to develop ...
 Reuters UK3 weeks ago Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan  4 Traders3 weeks ago Daiichi Sankyo Enters Into Clinical Collaboration Agreement in Japan for Anticoagulant Reversal Agent Andexanet Alfa  FirstWord Pharma3 weeks ago DAIICHI SANKYO : Enters Into Clinical Collaboration Agreement in Japan for Anticoagulant Reversal Agent Andexanet Alfa  4 Traders3 weeks ago
[x]  

Daiichi Sankyo reports positive phase 3 trial results of denosumab in patients with rheumatoid arthritis

Global pharmaceutical company, Daiichi Sankyo Company Limited, announced that phase 3 clinical trials for AMG 162 (denosumab), a gene recombinant drug for patients with rheumatoid arthritis, has achieved a major objective. The study conducted in ...
 PharmaBiz4 weeks ago DAIICHI SANKYO : Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment  4 Traders1 month ago Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment  FirstWord Pharma1 month ago

Daiichi Sankyo seeks Japanese approval for manufacturing & sales of narcotic analgesic hydromorphone HCl

Daiichi Sankyo Company, Limited (Daiichi Sankyo), a global pharmaceutical company, announced that the company has filed an application for the manufacture and sales in Japan of hydromorphone hydrochloride oral formulation (extended-release and ...
 PharmaBiz4 weeks ago DAIICHI SANKYO : Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride  4 Traders1 month ago Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride  FirstWord Pharma4 weeks ago

MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial

) - MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi ...
 Sys-Con Belgium5 days ago
[x]  

Effient for Certain ACS-PCI Patients With STEMI and NSTE-ACS Supported by DAPT Guideline Update

—Daiichi Sankyo Company, Limited and Eli Lilly and Company announced that the new American College of Cardiology (ACC)/American Heart Association (AHA) guideline-focused update provided the companies oral antiplatelet therapy Effient (prasugrel) ...
 Cardiac Interventions Today4 weeks ago New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS  BioSpace4 weeks ago ELI LILLY : New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS  4 Traders4 weeks ago
[x]  
BioPharma-Reporter.com

Daiichi Sankyo : Offers Assistance to Victims of the 2016 Kumamoto Earthquake

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders1 week ago Daiichi Sankyo: looming Benicar patent loss and large molecule focus prompted plant closure  BioPharma-Reporter.com3 weeks ago Daiichi Sankyo announces closure of its Hiratsuka Plant  Bio Spectrum Asia3 weeks ago Daiichi Sankyo to close down its DSCP Hiratsuka plant  PharmaBiz4 weeks ago
[x]  

Daiichi Sankyo and partners to research on capillary stem cells

Daiichi Sankyo has entered into a research collaboration with Mitsubishi UFJ Capital and Asahikawa Medical University to develop new capillary stem cells (CapSCs) into a cell source for regenerative medicine and cell therapy. CapSCs have been ...
 Pharmaceutical Technology3 weeks ago
Global Information Inc

Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets

20
 Yahoo! Finance3 days ago Global Idiopathic (Essential) Hypertension Pipeline Report 2016 - Review of 12 Companies & their Drug Profiles - Research and Markets  Digital Journal1 week ago Anaplastic Thyroid Cancer Pipeline Review, H1 2016 Featuring Daiichi Sankyo, Exelixis, Genelux, Immune Pharmaceuticals, Millennium Pharma, Novartis & Plexxikon - Research and Markets  4 Traders1 month ago Global Endocrinology Drugs Market to Set at CAGR of 6.69% Between 2016-2020: MarketResearchReports.biz  Digital Journal2 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo company
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
Happening by Location Click on any location on map to view latest news by location
 
More     Less